ERBB2 and breast cancer: Over-expression of EGFR/HER2 and downregulation of ER are molecular markers associated with de novo and acquired resistance to endocrine therapy in both pre-clinical models of breast cancer and in clinical studies (Knowlden et al, 2003; Schiff et al, 2005).